Search - tctmd.com

Displaying 1 - 20 of 551

Sort: Relevancy | Date

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

News Daily News

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

January 08, 2026

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Presentation TCT 2025

TCT 713: Outcomes of Left Atrial Appendage Occlusion vs. Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis

Presenter: Zeyad Kholeif

October 27, 2025

Presentation TCT 2025

TCT 710: Plug It or Drug It? Left Atrial Appendage Occlusion vs Direct Acting oral Anticoagulants: A Propensity Matched Real World Analysis of 5-year Outcomes for patients with Atrial Fibrillation

Presenter: Pushan Aggarwal

October 27, 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

Frail Older Patients With AF May Fare Better Switching to DOAC

News Daily News

Frail Older Patients With AF May Fare Better Switching to DOAC

August 05, 2025

Low Bleeding Risk With Abelacimab in AF Patients Undergoing Invasive Procedures

News Daily News

Low Bleeding Risk With Abelacimab in AF Patients Undergoing Invasive Procedures

June 10, 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

News Conference News ESOC 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

May 29, 2025

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

May 16, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

March 10, 2025

DOACs Reduce Stroke, Increase Bleeding in ICH Survivors With AF

News Daily News

DOACs Reduce Stroke, Increase Bleeding in ICH Survivors With AF

March 06, 2025

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.